Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Motixafortide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Standard dosing | ACTIVE_COMPARATOR | For Cohort 1, motixafortide will be given on Day 4 between 6:00 and 8:00 pm. A second dose may be given on Day 6 between 6:00 and 8:00 p.m. if CD34+ cell collection goals are not met on Day 5 apheresis. |
| Cohort 2: Early dosing | EXPERIMENTAL | For Cohort 2, motixafortide will be given on Day 4 between 2:00 and 4:00 pm. A second dose may be given on Day 6 with goal of administration between 6:00 and 8:00 pm after completion of pheresis if clinically feasible. if CD34+ cell collection goals are not met on Day 5 apheresis. |
| Name | Type | Description |
|---|---|---|
| Motixafortide | DRUG | Dose = 1.25 mg/kg via subcutaneous injection |
| G-CSF | DRUG | Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection |
Inclusion Criteria: * Subjects must be between the ages of 18 and 78 years, inclusive. * Histologically confirmed multiple myeloma expected to receive high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) * Received ≥3 cycles but ≤6 cycles of daratumumab-based quadruplet indu...
Top 20 of 25 competitors
Motixafortide is an investigational small molecule being studied for use in Multiple Myeloma. It is being evaluated as part of a mobilization regimen, specifically following quad-induction therapy, to enhance the collection of stem cells for apheresis. The drug is currently in Phase 1 clinical development and is not yet approved.
Motixafortide is a small molecule that targets the CXCR4 receptor, which plays a role in stem cell mobilization. By blocking this receptor, it aims to release stem cells from the bone marrow into the bloodstream, facilitating their collection for transplantation in Multiple Myeloma patients.
Motixafortide is being developed by BioLineRx Ltd., a biopharmaceutical company. BioLineRx is publicly traded under the ticker symbol BLRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Multiple Myeloma.
Motixafortide is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing research is focused on assessing its pharmacodynamic effects and safety profile in patients with Multiple Myeloma.
Motixafortide has been studied in a Phase 1 clinical trial with the identifier NCT06547112. This completed trial, titled 'A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization,' enrolled 20 participants in the United States.
Motixafortide is also known by other names, including BL-8040 and BKT140. These alternative names may be used in scientific literature and clinical trial registries. Regardless of the name, they refer to the same investigational small molecule being developed by BioLineRx for Multiple Myeloma.